Abstract 130P
Background
Neoadjuvant treatment of immune checkpoint inhibitors have shown a high pathologic complete response (pCR) rate in patients with dMMR/MSI-H, locally advanced colorectal cancer (LACRC). Cadonilimab (AK104), a novel bispecific antibody simultaneously targeting PD-1 and CTLA-4, was designed to boost anti-tumor activity with a favorable safety profile. Here, we primary reported the efficacy and safety of AK104 in the neoadjuvant treatment of dMMR/MSI-H LACRC, while concurrently exploring the potential for surgery avoidance.
Methods
The study was a multi-cohort, phase 2 trial, consisted of Cohort A (locally advanced colon cancer) and B (Locally Advanced Rectal Cancer). Patients (pts) with dMMR/MSI-H, LACRC were enrolled to receive AK104 (10mg/kg, iv, d1, q3w) for up to 8 cycles. The primary endpoint is the complete response rate (CR, pCR plus cCR). Secondary endpoints include MPR rate, R0 resection rate, DFS, OS, and safety.
Results
From April 2023 to August 2024, 34 pts were enrolled (26 in Cohort A and 8 in Cohort B). Baseline characteristics of pts are listed in the table. 34 pts had at least 2 cycles of treatment. In Cohort B, 4 pts completed the entire neoadjuvant treatment, and all reached the cCR. Currently, 13 pts (12 in Cohort A and 1 in Cohort B) received surgical resection, and the R0 resection rate was 100%. The pCR rate was 84.6% (11/13) and the MPR rate was 100 % (13/13). The median DFS was not reached. Treatment-related adverse events (TRAEs) occurred in 18/34(53%) pts. 5 /34 (14.7%) pts experienced grade 3-4 treatment-related adverse events (TRAEs), which included adrenocortical hypofunction (1 pt), myocarditis (1 pt), myositis (2 pts), and thrombocytopenia (1pt). No grade 5 AEs were observed. Table: 130P
| Characteristics | Cohort A, N=26 | Cohort B, N=8 |
| Age (years, median range) | 52 (18, 73) | 55 (48,68) |
| Gender | ||
| Female | 11 (42) | 1 (13) |
| Male | 15 (58) | 7 (87) |
| ECOG PS | ||
| 0 | 18 (69) | 6 (75) |
| 1 | 8 (31) | 2 (25) |
| Clinical T category | ||
| cT3 | 6 (23) | 5 (62) |
| cT4a | 20 (77) | 3 (38) |
| Clinical N category | ||
| N+ | 26 (100) | 7 (88) |
| N0 | 0 (0) | 1 (12) |
Conclusions
Cadonilimab showed promising efficacy with an outstanding pCR rate and manageable safety profile in locally advanced dMMR/MSI-H colorectal cancer patients. This trial is still ongoing and needs long-term follow-up.
Clinical trial identification
NCT05815290.
Legal entity responsible for the study
The authors.
Funding
Akeso Biopharma.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract